PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy

International Immunopharmacology

Volumn 10, Issue 12, 2010, Pages 1626-1629

  Majorczyk, Edyta ^a,b   Pawlik, Andrzej ^c   Kuśnierczyk, Piotr ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b OPOLE UNIVERSITY OF TECHNOLOGY   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Genetics; Methotrexate; PTPN22; Rheumatoid arthritis; Treatment response

Indexed keywords

DNA; FOLIC ACID; MEPREDNISONE; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RHEUMATOID FACTOR;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DNA ISOLATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VENOUS BLOOD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; TREATMENT OUTCOME;

EID: 78650013787     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.09.008     Document Type: Article

References (37)

1. J. Bowes, and A. Barton Recent advances in the genetics of RA susceptibility Rheumatology 47 2008 399 402
2. L. Klareskog, L. Padyukov, J. Ronnelid, and L. Alfresson Genes, environment and immunity in the development of rheumatoid arthritis Curr Opin Immunol 18 2006 650 655
3. M.A. Wilcox, Z. Li, W. Tapper, S. Browning, K. Curtin, and J. Ding Genetic association with rheumatoid arthritis - Genetic Analysis Workshop 15: summary of contributions from group 2 Genet Epidemiol 31 Suppl 1 2007 S12
4. T. Vang, M. Congia, M.D. Macis, L. Musumeci, V. Orru, and P. Zavattari Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant Nat Genet 37 2005 1317 1319
5. A.B. Begovich, V.E. Carlton, L.A. Honigberg, S.J. Schrodi, A.P. Chokkalingam, and H.C. Alexander A missense single nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis Am J Hum Genet 75 2004 330 337
6. P. Dieude, S. Garnier, L. Michou, E. Petit-Teixeira, E. Glikmans, and C. Pierlot European Consortium on Rheumatoid Arthritis Families: rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele Arthritis Res Ther 7 2005 R1200 R1207
7. P.K. Gregersen Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond Immunol Rev 204 2005 74 86
8. S. Mastana, A. Gilmour, A. Ghelani, H. Smith, and A. Samanta Association of PTPN22 with rheumatoid arthritis among South Asians in the UK J Rheumatol 34 2007 1984 1986
9. G. Orozco, B. Rueda, and J. Martin Genetic basis of rheumatoid arthritis Biomed Pharmacother 60 2006 656 662
10. E. Majorczyk, M. Jasek, R. Płoski, M. Wagner, A. Kosior, and A. Pawlik Association of PTPN22 single nucleotide polymorphism with rheumatoid arthritis but not with allergic asthma Eur J Hum Genet 15 2007 1043 1048
11. H. Kallberg, L. Padyukov, R.M. Plenge, J. Ronnelid, P.K. Gregersen, and A.H. van der Helm-van Mil Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis Am J Hum Genet 80 2007 867 875
12. D.M. Lee, and M.E. Weinblatt Rheumatoid arthritis Lancet 358 2001 903 911
13. D.P.M. Symmons Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome Best Pract Res Clin Rheumatol 16 2002 707 722
14. J. Świerkot, and J. Szechiński Methotrexate in rheumatoid arthritis Pharmacol News 58 2006 473 492
15. A. Pawlik, M. Herczyńska, M. Kurzawski, K. Safranow, V. Dziedziejko, and Z. Juzyszyn IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide Pharmacol Rep 61 2009 281 287
16. Y.H. Lee, and G.G. Song Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis Clin Drug Investig 30 2010 101 108
17. T. Pincus, J.A. Summey, S.A. Soraci Jr., K.A. Wallston, and N.P. Hummon Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26 1983 1346 1353
18. F. Wolfe, J.R. O'Dell, A. Kavanaugh, K. Wilske, and T. Pincus Evaluating severity and status in rheumatoid arthritis J Rheumatol 28 2001 1453 1462
19. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, M. Chernoff, and B. Fried The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials Arthritis Rheum 36 1993 729 740
20. D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, and C. Goldsmith American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 727 735
21. N. Bottini, L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, and M. Rostamkhani A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes Nat Genet 36 2004 337 338
22. N. Bottini, T. Vang, F. Cucca, and T. Mustelin Role of PTPN22 in type 1 diabetes and other autoimmune diseases Semin Immunol 18 2006 207 213
23. P.K. Gregersen, H.S. Lee, F. Batliwalla, and A.B. Begovich PTPN22: setting thresholds for autoimmunity Semin Immunol 18 2006 214 223
24. M. Rieck, A. Arechiga, S. Onengut-Gumuscu, C. Greenbaum, P. Concannon, and J.H. Buckner Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes J Immunol 179 2007 4704 4710
25. G. Orozco, D. Pascual-Salcedo, M.A. López-Nevot, T. Cobo, A. Cabezón, and E. Martín-Mola Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis Rheumatology (Oxford) 47 2007 138 141
26. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
27. A. Johnston, J.E. Gudjonsson, H. Sigmundsdottir, B.R. Ludviksson, and H. Valdimarsson The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules Clin Immunol 114 2005 154 163
28. P. Emery, F. Breedveld, S. Hall, P. Durez, D.J. Chang, and D. Robertson Comparison of methotrexate monotherapy with a combination of methotrexate with etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial Lancet 372 2008 375 382
29. V.E. Carlton, X. Hu, A.P. Chokkalingam, S.J. Schrodi, S. Brandon, and H.C. Alexander PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis Am J Hum Genet 77 2005 567 581
30. A. Hinks, S. Eyre, A. Barton, W. Thomson, and J. Worthington Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK Ann Rheum Dis 66 2007 683 686
31. M.K. Viken, M. Olsson, S.T. Flam, O. Forre, T.K. Kvien, and E. Thorsby The PTPN22 promoter polymorphism - 1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material Tissue Antigens 70 2007 190 197
32. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls Nature 447 2007 661 678
33. K. Stark, J. Rovensky, S. Blazickova, H. Grosse-Wilde, S. Ferencik, and C. Hengstenberg Association of common polymorphisms in known susceptibility genes with rheumatoid arthritis in a Slovak population using osteoarthritis patients as controls Arthritis Res Ther 11 2009 R70 R79
34. G. Orozco, A. Hinks, S. Eyre, X. Ke, L.J. Gibbons, and J. Bowes Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23 Hum Mol Genet 18 2009 2693 2699
35. T.U. Han, S.Y. Bang, C. Kang, and S.C. Bae TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians Arthritis Rheum 60 2009 2577 2584
36. W.M. Kooloos, T.W. Huizinga, H.J. Guchelaar, and J.A. Wessels Pharmacogenetics in treatment of rheumatoid arthritis Curr Pharm Des 16 2010 164 175
37. C. Bansard, T. Lequerre, T. Daveau, O. Boyer, F. Tron, and J.P. Salier Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford) 48 2009 1021 1028